broad_id
string | depmap_id
string | ccle_name
string | screen_id
string | upper_limit
int64 | lower_limit
float64 | slope
float64 | r2
float64 | auc
float64 | ec50
float64 | ic50
float64 | name
string | moa
string | target
string | disease.area
string | indication
string | smiles
string | phase
string | passed_str_profiling
bool | row_name
string |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BRD-K64881305-001-03-7 | ACH-000958 | SW48_LARGE_INTESTINE | MTS010 | 1 | 0.408401 | 3.788706 | 0.575352 | 0.566866 | 0.008208 | 0.012847 | ispinesib | kinesin inhibitor | KIF11 | null | null | CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1 | Phase 2 | true | ACH-000958 |
BRD-K69001009-001-02-8 | ACH-000958 | SW48_LARGE_INTESTINE | MTS010 | 1 | 0.534491 | 10.237352 | 0.338938 | 0.568885 | 0.001249 | null | golvatinib | VEGFR inhibitor | KDR, MET | null | null | CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1 | Phase 2 | true | ACH-000958 |
BRD-K76210423-001-01-6 | ACH-000958 | SW48_LARGE_INTESTINE | MTS010 | 1 | 0.93763 | -0.142721 | -0.052545 | 0.959586 | 6.614382 | null | resiquimod | toll-like receptor agonist | TLR7, TLR8 | null | null | CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O, CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O | Phase 3 | true | ACH-000958 |
BRD-K76239644-001-02-6 | ACH-000958 | SW48_LARGE_INTESTINE | MTS010 | 1 | 0.836113 | 6.772489 | 0.225156 | 0.917803 | 0.076937 | null | BMS-690514 | EGFR inhibitor, VEGFR inhibitor | EGFR, ERBB2, FLT3, KDR | null | null | COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1 | Phase 2 | true | ACH-000958 |
BRD-K81418486-001-44-2 | ACH-000958 | SW48_LARGE_INTESTINE | MTS010 | 1 | 0.057092 | -0.37988 | -0.122903 | 0.85259 | 0.000357 | null | vorinostat | HDAC inhibitor | HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9 | hematologic malignancy | cutaneous T-cell lymphoma (CTCL) | ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1 | Launched | true | ACH-000958 |
BRD-K85402309-043-01-9 | ACH-000958 | SW48_LARGE_INTESTINE | MTS010 | 1 | 0.545138 | 0.076464 | 0.009904 | 0.744756 | 0.001527 | null | dovitinib | EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB | null | null | CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O | Phase 3 | true | ACH-000958 |
BRD-K87782578-001-01-4 | ACH-000958 | SW48_LARGE_INTESTINE | MTS010 | 1 | 0.412638 | 0.205608 | -0.231114 | 0.794373 | 2.007451 | null | AVL-292 | Bruton's tyrosine kinase (BTK) inhibitor | BTK, YES1 | null | null | COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1 | Phase 2 | true | ACH-000958 |
BRD-K92723993-001-17-4 | ACH-000958 | SW48_LARGE_INTESTINE | MTS010 | 1 | 1.035477 | -0.049202 | 0.001009 | 1 | 209,409.865091 | null | imatinib | Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor | ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET | hematologic malignancy, oncology | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST) | CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1 | Launched | true | ACH-000958 |
BRD-K99113996-001-02-0 | ACH-000958 | SW48_LARGE_INTESTINE | MTS010 | 1 | 0.727959 | 5.712422 | -0.087415 | 0.82357 | 0.018476 | null | AZD2014 | mTOR inhibitor | MTOR | null | null | CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C | Phase 2 | true | ACH-000958 |
BRD-K99749624-001-07-0 | ACH-000958 | SW48_LARGE_INTESTINE | MTS010 | 1 | 0.52648 | 0.330951 | 0.024115 | 0.795662 | 0.21301 | null | linifanib | PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK | null | null | Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3[nH]nc(N)c23)c1 | Phase 3 | true | ACH-000958 |
BRD-M97302542-001-04-4 | ACH-000958 | SW48_LARGE_INTESTINE | MTS010 | 1 | 1.364167 | 1.514354 | 0.363717 | 1 | 0.141972 | null | dichloroacetate | pyruvate dehydrogenase kinase inhibitor | PDK1 | null | null | [Na].OC(=O)C(Cl)Cl, [Na].OC(=O)C(Cl)Cl | Phase 3 | true | ACH-000958 |
BRD-A25234499-001-19-1 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.981574 | 0.675092 | 0.026495 | 0.990641 | 0.071895 | null | aminoglutethimide | glucocorticoid receptor antagonist | CYP11A1, CYP19A1 | endocrinology, oncology | Cushing's syndrome, breast cancer | CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1 | Launched | true | ACH-000959 |
BRD-A70858459-001-01-7 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | -3.022394 | 1.464291 | -0.074823 | 0.963525 | 38.762509 | null | estramustine | DNA alkylating agent | ESR1, ESR2, MAP1A, MAP2 | oncology | prostate cancer | C[C@]12CCC3C(CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)C1CC[C@@H]2O | Launched | true | ACH-000959 |
BRD-A74914197-001-02-9 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.417737 | 1.810307 | 0.802658 | 0.654147 | 0.001959 | 0.005309 | pralatrexate | dihydrofolate reductase inhibitor | DHFR, TYMS | hematologic malignancy | peripheral T-cell lymphoma (PTCL) | Nc1nc(N)c2nc(CC(CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1 | Launched | true | ACH-000959 |
BRD-K02113016-001-19-6 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.555631 | 2.437992 | 0.520052 | 0.911082 | 1.439517 | null | olaparib | PARP inhibitor | PARP1, PARP2 | oncology | ovarian cancer | Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1, Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1 | Launched | true | ACH-000959 |
BRD-K02130563-001-11-4 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.100975 | 1.669545 | 0.860953 | 0.703149 | 0.406989 | 0.465871 | panobinostat | HDAC inhibitor | HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9 | hematologic malignancy | multiple myeloma | Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1 | Launched | true | ACH-000959 |
BRD-K03390685-001-01-7 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.524067 | 1.050819 | 0.235378 | 0.899371 | 1.444065 | null | cobimetinib | MEK inhibitor | null | oncology | melanoma | OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1 | Launched | true | ACH-000959 |
BRD-K03406345-001-21-1 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.514949 | 0.633813 | 0.538007 | 0.848118 | 0.599934 | null | azacitidine | DNA methyltransferase inhibitor | DNMT1, DNMT3A | hematologic malignancy, hematology | myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL) | Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000959 |
BRD-K03449891-001-08-6 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.578468 | 2.295438 | 0.750745 | 0.881837 | 0.659049 | null | foretinib | VEGFR inhibitor | FLT1, FLT4, KDR, MET | null | null | COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1 | Phase 2 | true | ACH-000959 |
BRD-K03765900-001-01-9 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.056133 | 4.78609 | 0.706607 | 0.961022 | 6.924143 | 7.098608 | XL-647 | EGFR inhibitor, VEGFR inhibitor | EGFR, EPHB4, ERBB2, FLT4, KDR | null | null | COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1 | Phase 3 | true | ACH-000959 |
BRD-K05804044-001-18-5 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 1.026671 | -0.035181 | -0.0034 | 1 | 13.587542 | null | AZ-628 | RAF inhibitor | BRAF, RAF1 | null | null | Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1 | Preclinical | true | ACH-000959 |
BRD-K06814349-304-02-7 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.196178 | 2.457333 | 0.877988 | 0.777677 | 0.683187 | 0.836719 | fosbretabulin | tubulin polymerization inhibitor, VE-cadherin antagonist | CDH5 | null | null | COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O | Phase 3 | true | ACH-000959 |
BRD-K08109215-001-06-4 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.635162 | 0.425977 | 0.439536 | 0.871347 | 0.514282 | null | I-BET-762 | bromodomain inhibitor | BRD2, BRD3, BRD4 | null | null | CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 | Phase 2 | true | ACH-000959 |
BRD-K08542803-001-02-3 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.05644 | -2.788228 | -0.000989 | 0.999278 | 0.000152 | null | gambogic-acid | caspase activator | BCL2 | null | null | CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C | Phase 2 | true | ACH-000959 |
BRD-K08547377-001-04-4 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.456267 | 1.052183 | 0.861458 | 0.668963 | 0.015376 | 0.155779 | irinotecan | topoisomerase inhibitor | TOP1, TOP1MT | oncology | colorectal cancer | CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12 | Launched | true | ACH-000959 |
BRD-K08703257-001-13-9 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 1.020332 | 0.135233 | -0.062675 | 1 | 88.760182 | null | 3-amino-benzamide | PARP inhibitor | PARP1 | null | null | NC(=O)c1cccc(N)c1, NC(=O)c1cccc(N)c1 | Phase 2 | true | ACH-000959 |
BRD-K08799216-001-05-3 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.286875 | 0.689186 | 0.679696 | 0.644166 | 0.078938 | 0.272044 | pelitinib | EGFR inhibitor | EGFR | null | null | CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C | Phase 2 | true | ACH-000959 |
BRD-K09951645-001-11-8 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.716297 | 9.839279 | 0.69899 | 0.93953 | 1.263732 | null | dabrafenib | RAF inhibitor | BRAF, LIMK1, NEK11, RAF1, SIK1 | oncology | melanoma | CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F | Launched | true | ACH-000959 |
BRD-K11630072-001-13-2 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.425259 | 0.90658 | 0.764546 | 0.749784 | 0.148694 | 1.209943 | carmofur | thymidylate synthase inhibitor | TYMS | oncology | breast cancer, colorectal cancer | CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O | Launched | true | ACH-000959 |
BRD-K12184916-001-19-6 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.354724 | 1.618971 | 0.738371 | 0.61249 | 0.028631 | 0.06143 | NVP-BEZ235 | mTOR inhibitor, PI3K inhibitor | ATR, MTOR, PIK3CA, PIK3CD, PIK3CG | null | null | Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1, Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1 | Phase 2 | true | ACH-000959 |
BRD-K12343256-001-14-7 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.650302 | 1.126928 | 0.282304 | 0.878743 | 0.352421 | null | trametinib | MEK inhibitor | MAP2K1, MAP2K2 | oncology | melanoma | CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O | Launched | true | ACH-000959 |
BRD-K13049116-001-04-0 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.855029 | 4.123324 | 0.043306 | 0.991275 | 5.705419 | null | BMS-754807 | IGF-1 inhibitor | AKT1, IGF1R | null | null | C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1 | Phase 2 | true | ACH-000959 |
BRD-K13390322-001-06-3 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 1.300182 | 2.387111 | 0.279551 | 1 | 0.169422 | null | AT-7519 | CDK inhibitor | CDK1, CDK2, CDK4, CDK5, CDK6, CDK9 | null | null | Clc1cccc(Cl)c1C(=O)Nc1c[nH]nc1C(=O)NC1CCNCC1 | Phase 2 | true | ACH-000959 |
BRD-K13514097-001-04-6 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.561924 | 0.149111 | 0.111078 | 0.76074 | 0.021384 | null | everolimus | mTOR inhibitor | MTOR | oncology, neurology/psychiatry, genetics, urology | breast cancer, neuroendocrine tumors of pancreatic origin (PNET), renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), tuberous sclerosis complex (TSC), renal angiomyolipoma | CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO | Launched | true | ACH-000959 |
BRD-K13662825-001-07-5 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.028079 | 1.528436 | 0.868076 | 0.637384 | 0.06716 | 0.069748 | dinaciclib | CDK inhibitor | CDK1, CDK2, CDK5, CDK9 | null | null | CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO | Phase 3 | true | ACH-000959 |
BRD-K14109347-001-03-4 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.401931 | 1.862804 | 0.647495 | 0.896924 | 1.92392 | 4.612722 | LY2603618 | CHK inhibitor | CHEK1 | null | null | Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1, Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1 | Phase 2 | true | ACH-000959 |
BRD-K15179879-001-03-2 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.079473 | 0.73676 | 0.812265 | 0.414164 | 0.018988 | 0.024017 | carfilzomib | proteasome inhibitor | PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9 | hematologic malignancy | multiple myeloma | CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1 | Launched | true | ACH-000959 |
BRD-K15600710-066-05-8 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.212435 | 3.451651 | 0.851941 | 0.717687 | 0.302865 | 0.355511 | obatoclax | BCL inhibitor | BCL2 | null | null | COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1, COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 | Phase 3 | true | ACH-000959 |
BRD-K16730910-001-10-7 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.398337 | 3.632927 | 0.649777 | 0.958483 | 5.249945 | 8.139179 | regorafenib | FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK | oncology | colorectal cancer, gastrointestinal stromal tumors (GIST) | CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1 | Launched | true | ACH-000959 |
BRD-K17555800-003-02-3 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.969968 | -0.283742 | 0.021847 | 0.986118 | 0.04224 | null | talmapimod | p38 MAPK inhibitor | MAPK11, MAPK14 | null | null | C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C | Phase 2 | true | ACH-000959 |
BRD-K17610631-001-03-3 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.225096 | 2.380466 | 0.962714 | 0.687269 | 0.192861 | 0.247958 | indisulam | CDK inhibitor | CA1, CA12, CA14, CA2, CA6, CA7, CA9 | null | null | NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12 | Phase 2 | true | ACH-000959 |
BRD-K17743125-001-08-4 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.663914 | 0.126851 | 0.029793 | 0.851115 | 0.502585 | null | belinostat | HDAC inhibitor | HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9 | hematologic malignancy | peripheral T-cell lymphoma (PTCL) | ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1 | Launched | true | ACH-000959 |
BRD-K18961567-001-01-1 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.849534 | 0.297379 | 0.034439 | 0.91868 | 0.041322 | null | LY2801653 | MET inhibitor | MET | null | null | Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1 | Phase 2 | true | ACH-000959 |
BRD-K19540840-001-09-4 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.830887 | 0.25475 | 0.039973 | 0.935471 | 0.654687 | null | saracatinib | src inhibitor | ABL1, LCK, SRC, YES1 | null | null | CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1 | Phase 2/Phase 3 | true | ACH-000959 |
BRD-K19687926-001-04-1 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.676214 | 0.505687 | 0.089817 | 0.868041 | 0.228539 | null | lapatinib | EGFR inhibitor | EGFR, ERBB2 | oncology | breast cancer | CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1 | Launched | true | ACH-000959 |
BRD-K19796430-001-05-6 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.923543 | 0.030411 | -0.013155 | 0.962766 | 0.433892 | null | sonidegib | smoothened receptor antagonist | SMO | oncology | basal cell carcinoma (BCC) | C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1, C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1 | Launched | true | ACH-000959 |
BRD-K22064724-001-01-8 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.055303 | 6.268423 | 0.697168 | 0.831434 | 1.769937 | 1.803309 | napabucasin | STAT inhibitor | STAT3 | null | null | CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O, CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O | Phase 3 | true | ACH-000959 |
BRD-K22822991-001-02-3 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.778551 | 0.475425 | 0.335327 | 0.875699 | 0.037677 | null | odanacatib | cathepsin inhibitor | CTSK | null | null | CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N | Phase 3 | true | ACH-000959 |
BRD-K23228615-001-02-8 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.287216 | 4.12224 | 0.74877 | 0.893948 | 2.361534 | 2.905368 | GDC-0980 | mTOR inhibitor, PI3K inhibitor | FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK | null | null | C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1 | Phase 2 | true | ACH-000959 |
BRD-K23984367-001-07-5 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.657713 | 3.753452 | 0.733795 | 0.927997 | 1.298559 | null | sorafenib | FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET | oncology | renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC) | CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1 | Launched | true | ACH-000959 |
BRD-K26026438-001-01-0 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.582562 | 0.811999 | 0.245399 | 0.895665 | 1.060453 | null | tucatinib | EGFR inhibitor | ERBB2 | null | null | Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1 | Phase 2 | true | ACH-000959 |
BRD-K26657438-001-15-2 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.891618 | 0.390449 | 0.063656 | 0.937195 | 0.027304 | null | imiquimod | interferon inducer, toll-like receptor agonist | TLR7, TLR8 | dermatology, infectious disease, oncology | actinic keratosis (AK), genital warts, basal cell carcinoma (BCC) | CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12 | Launched | true | ACH-000959 |
BRD-K28822270-001-03-7 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | -0.234866 | 1.357061 | 0.785199 | 0.90493 | 6.909501 | 5.202592 | resminostat | HDAC inhibitor | HDAC1, HDAC3, HDAC6, HDAC8 | null | null | CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO | Phase 2 | true | ACH-000959 |
BRD-K29905972-001-06-3 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 1.081171 | 0.468711 | -0.163043 | 1 | 0.268408 | null | axitinib | PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1, FLT1, FLT4, KDR, PLK4 | oncology | renal cell carcinoma (RCC) | CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1 | Launched | true | ACH-000959 |
BRD-K30577245-001-05-0 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.108639 | 2.407717 | 0.804431 | 0.720026 | 0.029655 | 0.03283 | docetaxel | tubulin polymerization inhibitor | BCL2, MAP2, MAP4, MAPT, NR1I2, TUBB, TUBB1 | oncology | breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC) | CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C | Launched | true | ACH-000959 |
BRD-K31698212-001-02-9 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.800789 | 1.410688 | 0.258616 | 0.918278 | 0.187086 | null | icotinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1 | Launched | true | ACH-000959 |
BRD-K31928526-001-02-1 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.248122 | 3.973404 | 0.693237 | 0.753495 | 0.415154 | 0.493348 | barasertib | Aurora kinase inhibitor | AURKA, AURKB | null | null | CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(O)(O)=O | Phase 2/Phase 3 | true | ACH-000959 |
BRD-K33379087-001-07-5 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.215606 | 3.579643 | 0.837568 | 0.859758 | 1.764821 | 2.066135 | tivantinib | tyrosine kinase inhibitor | MET | null | null | O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23 | Phase 3 | true | ACH-000959 |
BRD-K33610132-001-02-9 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 1.14203 | 0.353839 | -0.155872 | 1 | 0.008737 | null | rociletinib | EGFR inhibitor | EGFR | null | null | COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O | Phase 3 | true | ACH-000959 |
BRD-K33622447-066-01-9 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.50124 | 1.565079 | 0.678475 | 0.82562 | 0.337129 | null | abemaciclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1 | Launched | true | ACH-000959 |
BRD-K35520305-001-16-9 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.87015 | -0.320493 | 0.022012 | 0.968347 | 0.001235 | null | dacarbazine | DNA alkylating agent | PGD, POLA2 | oncology, hematologic malignancy | melanoma, Hodgkin's lymphoma | CN(C)\N=N\c1[nH]cnc1C(N)=O, CN(C)\N=N\c1[nH]cnc1C(N)=O | Launched | true | ACH-000959 |
BRD-K36627727-001-05-4 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.895506 | 0.819038 | 0.132241 | 0.93429 | 0.021121 | null | tamibarotene | retinoid receptor agonist | RARA, RARB | hematologic malignancy | acute promyelocytic leukemia (APL) | CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12 | Launched | true | ACH-000959 |
BRD-K36788280-001-01-2 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.874271 | 0.271507 | 0.06322 | 0.915871 | 0.004116 | null | ribociclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1 | Launched | true | ACH-000959 |
BRD-K37379014-001-02-0 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.112922 | 0.699419 | 0.609554 | 0.572539 | 0.001471 | 0.002121 | filanesib | kinesin inhibitor, kinesin-like spindle protein inhibitor | KIF11 | null | null | CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F | Phase 3 | true | ACH-000959 |
BRD-K38332599-001-01-3 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.148645 | 1.509464 | 0.857964 | 0.773425 | 0.76598 | 0.967679 | uprosertib | AKT inhibitor | AKT1, AKT2, AKT3 | null | null | Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1 | Phase 2 | true | ACH-000959 |
BRD-K38527262-300-01-0 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.150338 | 13.508882 | 0.931898 | 0.818612 | 1.159603 | 1.19071 | atiprimod | JAK inhibitor, STAT inhibitor | JAK2, STAT3 | null | null | CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1 | Phase 2 | true | ACH-000959 |
BRD-K38852836-001-02-1 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.204812 | 3.172314 | 0.877303 | 0.540898 | 0.009235 | 0.010903 | ganetespib | HSP inhibitor | HSP90AA1 | null | null | CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O | Phase 3 | true | ACH-000959 |
BRD-K39974922-001-04-3 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.864045 | -0.061588 | -0.030852 | 0.901387 | 613,319.564994 | null | lenvatinib | FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | FLT4, KDR | oncology | thyroid cancer | COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O | Launched | true | ACH-000959 |
BRD-K41859756-001-06-8 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.285262 | 2.209763 | 0.840564 | 0.666981 | 0.027218 | 0.0399 | NVP-AUY922 | HSP inhibitor | HSP90AA1, HSP90AB1 | null | null | CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O | Phase 2 | true | ACH-000959 |
BRD-K42495768-001-01-7 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | -0.701908 | 4.519822 | 0.881036 | 0.982142 | 11.261626 | 9.275402 | tasisulam | apoptosis stimulant | null | null | null | Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1 | Phase 3 | true | ACH-000959 |
BRD-K42805893-001-04-9 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | -3.533938 | 2.708558 | 0.300818 | 0.965189 | 17.384255 | 8.042382 | osimertinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12 | Launched | true | ACH-000959 |
BRD-K42828737-001-03-3 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.575902 | 3.758511 | 0.497134 | 0.889048 | 0.789538 | null | sunitinib | FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET | oncology | gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET) | CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C | Launched | true | ACH-000959 |
BRD-K42898655-001-01-8 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.722289 | 6.914626 | 0.613747 | 0.855243 | 0.00397 | null | temsirolimus | mTOR inhibitor | MTOR | oncology | renal cell carcinoma (RCC) | CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1OC(=O)C(C)(CO)CO | Launched | true | ACH-000959 |
BRD-K43389675-001-02-1 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.103327 | 5.046942 | 0.881073 | 0.845372 | 1.875913 | 1.963962 | daunorubicin | RNA synthesis inhibitor, topoisomerase inhibitor | TOP2A, TOP2B | hematologic malignancy | acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) | COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O | Launched | true | ACH-000959 |
BRD-K44227013-001-06-4 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.096332 | 0.740223 | 0.537896 | 0.817304 | 2.006463 | 2.679179 | ponatinib | Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor | ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK | hematologic malignancy | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) | CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1 | Launched | true | ACH-000959 |
BRD-K44408410-001-17-6 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.432233 | 0.404781 | 0.533866 | 0.848842 | 1.908094 | null | 2-methoxyestradiol | hypoxia inducible factor inhibitor | COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB | null | null | COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O | Phase 2 | true | ACH-000959 |
BRD-K44827188-001-06-0 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 1.00795 | 0.062667 | -0.004314 | 1 | 0.204122 | null | vismodegib | hedgehog pathway inhibitor, smoothened receptor antagonist | SMO | oncology | basal cell carcinoma (BCC) | Clc1cc(ccc1C(=O)Nc1ccc(Cl)c(c1)-c1ccccn1)S(C)(=O)=O | Launched | true | ACH-000959 |
BRD-K46386702-001-02-1 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.429253 | 0.345472 | 0.524383 | 0.77782 | 0.38301 | null | ARRY-334543 | EGFR inhibitor | ERBB2 | null | null | C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1 | Phase 2 | true | ACH-000959 |
BRD-K49328571-001-15-0 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 1.030077 | -0.191803 | -0.030019 | 1 | 4.455621 | null | dasatinib | Bcr-Abl kinase inhibitor, ephrin inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor, tyrosine kinase inhibitor | ABL1, ABL2, BLK, EPHA2, FGR, FRK, FYN, HCK, KIT, LCK, LYN, PDGFRB, SRC, SRMS, STAT5B, YES1 | hematologic malignancy | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) | Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1, Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1 | Launched | true | ACH-000959 |
BRD-K49350383-001-14-5 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 1.288271 | -0.310633 | 0.136787 | 1 | 0.00785 | null | thioguanine | purine antagonist | IMPDH1, IMPDH2 | hematologic malignancy | acute myeloid leukemia (AML) | Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1 | Launched | true | ACH-000959 |
BRD-K50010139-001-01-5 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.414352 | 0.144895 | 0.196572 | 0.670577 | 0.012849 | null | poziotinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | null | null | COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C, COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C | Phase 2 | true | ACH-000959 |
BRD-K50168500-001-07-9 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.213506 | 0.656299 | 0.601077 | 0.772143 | 0.768314 | 1.794974 | canertinib | EGFR inhibitor | AKT1, EGFR, ERBB2, ERBB4 | null | null | Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl | Phase 3 | true | ACH-000959 |
BRD-K51313569-001-07-8 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.639675 | 1.012992 | 0.716025 | 0.857075 | 0.2167 | null | palbociclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O | Launched | true | ACH-000959 |
BRD-K51791723-003-01-7 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | -0.062385 | 0.499362 | 0.633287 | 0.643694 | 0.551686 | 0.435946 | P276-00 | CDK inhibitor | CDK1, CDK4, CDK9 | null | null | CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl | Phase 2 | true | ACH-000959 |
BRD-K51967704-001-03-6 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.274635 | 1.953654 | 0.94795 | 0.688728 | 0.155398 | 0.233663 | BIIB021 | HSP inhibitor | HSP90AA1 | null | null | COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C | Phase 2 | true | ACH-000959 |
BRD-K52313696-001-12-3 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.652937 | -1.137595 | 0.156066 | 0.968015 | 0.001006 | null | tacedinaline | HDAC inhibitor | HDAC1 | null | null | CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N | Phase 3 | true | ACH-000959 |
BRD-K53414658-001-08-2 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 1.135165 | -0.487187 | -0.123356 | 1 | 0.235965 | null | tivozanib | VEGFR inhibitor | FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB | null | null | COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC | Phase 3 | true | ACH-000959 |
BRD-K53972329-001-07-0 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.814888 | -0.134723 | 0.005443 | 0.901128 | 0.223298 | null | ruxolitinib | JAK inhibitor | JAK1, JAK2, JAK3, TYK2 | hematologic malignancy, hematology | myelofibrosis, polycythemia vera | N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12 | Launched | true | ACH-000959 |
BRD-K54256913-001-08-7 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.136526 | 2.193676 | 0.859283 | 0.804644 | 1.117031 | 1.291814 | MK-1775 | WEE1 kinase inhibitor | WEE1 | null | null | CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1 | Phase 2 | true | ACH-000959 |
BRD-K54955827-001-02-2 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.685329 | 0.409034 | 0.246054 | 0.874305 | 0.286485 | null | niraparib | PARP inhibitor | PARP1 | oncology | primary peritoneal cancer (PPC) | NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1, NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1 | Launched | true | ACH-000959 |
BRD-K54997624-001-06-0 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.977966 | 0.295328 | 0.015432 | 0.993103 | 1.697596 | null | alpelisib | PI3K inhibitor | PIK3CA, PIK3CB, PIK3CD, PIK3CG | null | null | Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F | Phase 3 | true | ACH-000959 |
BRD-K55187425-236-05-2 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.183288 | 12.676544 | 0.911697 | 0.617272 | 0.105906 | 0.10979 | rigosertib | cell cycle inhibitor, PLK inhibitor | PLK1 | null | null | COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1 | Phase 3 | true | ACH-000959 |
BRD-K56343971-001-14-8 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.81053 | 1.49172 | 0.302057 | 0.95177 | 0.860064 | null | vemurafenib | RAF inhibitor | BRAF, RAF1 | oncology | melanoma | CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F | Launched | true | ACH-000959 |
BRD-K56981171-001-02-8 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.792122 | -4.29258 | 0.088591 | 0.874308 | 0.215629 | null | brigatinib | ALK tyrosine kinase receptor inhibitor, EGFR inhibitor | ALK, EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1 | Launched | true | ACH-000959 |
BRD-K57080016-001-15-9 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 11.178456 | 1.750355 | -0.051628 | 1 | 18,931.41753 | null | selumetinib | MEK inhibitor | MAP2K1 | null | null | Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO | Phase 3 | true | ACH-000959 |
BRD-K57169635-001-04-5 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.123608 | 0.610236 | 0.595255 | 0.765712 | 1.065355 | 1.69665 | dacomitinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | null | null | COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1 | Phase 3 | true | ACH-000959 |
BRD-K58435339-001-03-0 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.326846 | 1.944058 | 0.802073 | 0.625015 | 0.044889 | 0.077452 | AT13387 | HSP antagonist | HSP90AA1 | null | null | CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O | Phase 2 | true | ACH-000959 |
BRD-K58529924-001-01-5 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.214644 | 5.298069 | 0.839393 | 0.974599 | 8.053876 | 8.953208 | ONC201 | AKT inhibitor, MAP kinase inhibitor | TNFSF10 | null | null | Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O | Phase 2 | true | ACH-000959 |
BRD-K58550667-001-08-7 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.172189 | 5.768495 | 0.820654 | 0.644303 | 0.009656 | 0.010389 | FK-866 | niacinamide phosphoribosyltransferase inhibitor | NAMPT | null | null | O=C(NCCCCC1CCN(CC1)C(=O)c1ccccc1)\C=C\c1cccnc1 | Phase 2 | true | ACH-000959 |
BRD-K59317601-001-05-5 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.254775 | 3.249484 | 0.865439 | 0.688792 | 0.173758 | 0.216354 | MLN0128 | mTOR inhibitor | MTOR, PIK3CA, PIK3CD, PIK3CG | null | null | CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12 | Phase 2 | true | ACH-000959 |
Subsets and Splits
No saved queries yet
Save your SQL queries to embed, download, and access them later. Queries will appear here once saved.